Back

Therapeutic Spp1 silencing in TREM2+ cardiac macrophages suppresses atrial fibrillation

Momin, N.; Pabel, S.; Rudra, A.; Kumowski, N.; Lee, I.-H.; Mentkowski, K.; Yamazoe, M.; Stengel, L.; Muse, C. G.; Seung, H.; Paccalet, A.; Gonzalez-Correa, C.; Jacobs, E. B.; Grune, J.; Schloss, M. J.; Sossalla, S.; Wojtkiewicz, G.; Iwamoto, Y.; McMullen, P.; Mitchell, R. N.; Ellinor, P. T.; Anderson, D. G.; Naxerova, K.; Nahrendorf, M.; Hulsmans, M.

2024-08-10 immunology
10.1101/2024.08.10.607461 bioRxiv
Show abstract

Atrial fibrillation (AFib) and the risk of its lethal complications are propelled by fibrosis, which induces electrical heterogeneity and gives rise to reentry circuits. Atrial TREM2+ macrophages secrete osteopontin (encoded by Spp1), a matricellular signaling protein that engenders fibrosis and AFib. Here we show that silencing Spp1 in TREM2+ cardiac macrophages with an antibody-siRNA conjugate reduces atrial fibrosis and suppresses AFib in mice, thus offering a new immunotherapy for the most common arrhythmia.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.